Abstract
Dose Selection and Clinical Development of Efgartigimod PH20 Subcutaneous in Patients with Generalized Myasthenia Gravis (P1-5.017)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1212/wnl.0000000000203765
Journal: Neurology | Publication Date: Apr 25, 2023 |
Citations: 1 |
Dose Selection and Clinical Development of Efgartigimod PH20 Subcutaneous in Patients with Generalized Myasthenia Gravis (P1-5.017)
Join us for a 30 min session where you can share your feedback and ask us any queries you have